Selected Portfolio
RNA targeting platform focused on genetic, cardiometabolic and central nervous system diseases
Innovative gene-based immuno-oncology treatments for solid tumors
Clinical stage biologic treatments for oncology and inflammatory diseases
Novel, adaptive, controllable cell therapies for the treatment of patients with cancer and autoimmune diseases
Developing an easy-to-use and needle-free epinephrine nasal spray to treat severe allergies
Novel, oral small molecule therapeutics for neurodegenerative diseases
Company looking to in-license precision oncology assets with differentiated target product profiles
A new class of small, chemically synthesized medicines for oncology and beyond
Clinical-stage company leveraging Targeted Protein Degradation for novel therapeutics for oncology and inflammatory diseases
Transformative gene-based medicines for serious human diseases
Groundbreaking treatments to restore and improve hearing and balance
New class of molecules for degenerative disorders
Platform for selective depletion of disease-causing cells in oncology and other diseases
Targeting extrachromosomal DNA to treat cancer
Clinical stage oncology company pioneering a class of selective translation regulators
Highly selective medicines for functionally and genomically defined cancer patients
Harnessing the immune system to reveal optimal targets for each patient for cancer immunotherapies
Unlocking nature's regulatory mechanisms to fuel the discovery of new medicines
Clinical stage company developing a candidate for a targeted approach to hypertension
Advanced therapeutics for patients suffering from a range of autoimmune diseases
Targeting the ubiquitin pathway with a new class of drugs
A new generation of oral integrin therapies for the treatment of serious chronic diseases
Modulation of metabolism to address a wide range of diseases
Pioneering technologically-driven methods of drug discovery, to make therapeutics against the most challenging of targets
Improving upon the efficacy of cell therapy, making it more rapidly available to the broad population
A high-throughput proteomics platform to enable drug discovery
Focused on transforming lives of patients with immune dysfunctions and cancer
Glyco-sensing molecules designed to overcome resistance to first-generation immuno-oncology drugs
Therapeutics for localized immunomodulation at the site of disease for patients with autoimmune and inflammatory disease
Oral treatments for immune diseases
Taking a smarter approach to fertility and family building benefit solutions
Advanced inhaled anti-infectives for targeted treatment of life-threatening lung infections
Pioneering the integrated mapping of disease networks for precision therapeutics
Clinical stage company focused on orphan renal diseases
Proprietary, advanced microbiome drug discovery and development platform for therapeutics in a range of diseases.
Clinical stage company developing a novel IL-18 construct to treat oncology patients
Focused on identifying, developing and commercializing medicines for multi-drug resistant (MDR) bacterial infections and rare disease
Discovering innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases
Targeted cancer therapies designed to address treatment resistance and improve lives
Early stage company from the founders of CRISPR Therapeutics
NOTE: Selected portfolio companies are provided for illustrative purposes only, have been selected in order to provide examples of the operational experience of SR One’s professionals and do not purport to be a complete list thereof. Excludes certain investments which are no longer active and/or which have minimal value. Any portfolio company cited on this page may or may not be in the portfolio of a current fund managed by SR One. This list should not be construed as a recommendation of any particular investment or security.